Whether Pegcetacoplan-Empaveli is already on the market in the country

Pegcetacoplan (Pegcetacoplan) is not currently on the market in the country, nor is it included in the medical insurance system. This means that domestic patients cannot obtain the drug at regular hospitals or pharmacies. In overseas markets, Pegtak is mainly supplied through hospitals and professional pharmacies in European and American countries, and is used for the treatment of adult PNH and C3-related kidney diseases. The main reasons for not being launched in the domestic market include that the drug registration and approval process has not been completed, the lack of local clinical data and the requirements for drug safety and efficacy verification. Domestic regulatory agencies usually require new drugs to provide sufficient clinical evidence, quality control information and safety data before introduction to ensure patient drug safety.

Although it is not yet on the market in China, overseas studies and guidelines show that Pegtak has unique clinical value inPNH and C3-related kidney diseases. In patients with PNH, PEGATOX can improve anemia and related organ damage while reducing transfusion dependence by inhibiting C3-mediated intravascular hemolysis. For patients with C3G or IC-MPGN, PegTac reduces proteinuria and delays the decline of renal function by regulating complement C3 activity. Overseas clinical practice also emphasizes individualized treatment strategies. Doctors will adjust the dose and frequency of administration according to the patient's age, weight, underlying diseases, and previous medication.

If domestic patients need information about Pegtak, they can obtain it through formal overseas clinical guidelines, international academic conferences and drug registration information. At the same time, patients who potential cross-border drug purchases should strictly follow professional medical guidance to ensure that the sources of drugs are legal and of reliable quality, and individualized plans should be developed based on doctor evaluation.

Generally speaking, although Pegtak has not been marketed in China, its clinical value and usage experience provide an important reference for its future introduction into the domestic market, and also provide treatment ideas and scientific guidance for patients with related diseases.

Reference materials:https://empaveli.com/